The EUropean Network of National Schizophrenia Networks Studying Gene&#8211;Environment Interactions (EU-GEI): Incidence and First-Episode Case&#8211;Control Programme by Gayer-Anderson, C. et al.
1 
 
 
1 
 
The EUropean Network of National Schizophrenia Networks Studying Gene-
Environment Interactions (EU-GEI) – Incidence and First-Episode Case-Control 
Programme 
 
Charlotte Gayer-Anderson1, Hannah E Jongsma2,3, Marta Di Forti4, Diego Quattrone4, Eva 
Velthorst5,6,7, Lieuwe de Haan7, Jean-Paul Selten8,9, Andrei Szöke10,11,12, Pierre-Michel Llorca13, Andrea 
Tortelli14, Celso Arango15, Julio Bobes16, Miguel Bernardo17, Julio Sanjuán18, José Luis Santos19, Manuel 
Arrojo20, Mara Parellada15, Ilaria Tarricone21, Domenico Berardi21, Mirella Ruggeri22, Antonio 
Lasalvia22,23, Laura Ferraro24, Caterina La Cascia24, Daniele La Barbera24, Paulo Rossi Menezes25, 
Cristina Marta Del-Ben26, EU-GEI WP2 Group††, Bart P Rutten9, Jim van Os9,27,28, Peter B Jones3,29, 
Robin M Murray28, James B Kirkbride2, Craig Morgan1* 
 
Correspondence to: Craig Morgan, Department of Health Services and Population Research, Institute 
of Psychiatry, Psychology & Neuroscience, King’s College London, 16 De Crespigny Park, London, SE5 
8AF, England (email: craig.morgan@kcl.ac.uk; telephone: +44 (0)20 7848 0351) 
 
Author affiliations: 
1Department of Health Services and Population Research, Institute of Psychiatry, Psychology & 
Neuroscience, King’s College London, London, England 
2PsyLife Group, Division of Psychiatry, University College London, London, England 
3Department of Psychiatry, University of Cambridge, Cambridge, England 
4Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & 
Neuroscience, King’s College London, London, England 
5Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA 
2 
 
 
2 
 
6Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New 
York, USA 
7Early Psychosis Section, Department of Psychiatry, Academic Medical Centre, University of 
Amsterdam, Amsterdam, the Netherlands 
8GGZ Rivierduinen, Institute for Mental Health, Leiden, the Netherlands 
9Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, 
Maastricht University Medical Centre, Maastricht, the Netherlands 
10Institut National de la Santé et de la Recherche Médicale, U955, Equipe 15 Neuro-Psychiatrie 
Translationnelle, Créteil, France 
11AP-HP, Pôle de Psychiatrie des Hôpitaux Universitaires Henri Mondor, Créteil, France 
12Fondation FondaMental, Créteil, France 
13EA 7280 Npsydo, Université Clermont Auvergne, Clermont-Ferrand, France. 
14Establissement Public de Santé, Maison Blanche, Paris, France 
15Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, 
School of Medicine, Universidad Complutense, ISGM, CIBERSAM, Madrid, Spain 
16Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de 
Investigación Biomédica en Red de Salud Mental, Oviedo, Spain 
17Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic, Department of 
Medicine, University of Barcelona, Institut d’Investigacions Biomèdiques, August Pi I Sunyer, Centro 
de Investigación Biomédica en Red de Salud Mental, Barcelona, Spain 
18Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigación 
Biomédica en Red de Salud Mental, Valencia, Spain 
19Department of Psychiatry, Hospital "Virgen de la Luz," Cuenca, Spain 
20Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigación Sanitaria de 
Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Spain 
3 
 
 
3 
 
21Department of Biomedical and NeuroMotor Sciences, Psychiatry Unit, Alma Mater Studiorium 
Università di Bologna, Bologna, Italy  
22Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of 
Verona, Verona, Italy 
23Section of Psychiatry, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy 
24Department of Experimental Biomedicine and Clinical Neuroscience, Section of Psychiatry, 
University of Palermo, Palermo, Italy 
25Department of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, 
Brazil 
26Division of Psychiatry, Department of Neuroscience and Behaviour, Ribeirão Preto Medical School, 
Universidade de São Paulo, São Paulo, Brazil 
27Department of Psychiatry, Brain Center Rudolf Magnus, Utrecht University Medical Centre, Utrecht, 
the Netherlands 
28Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King’s College 
London, London, England 
29CAMEO Early Intervention Service, Cambridgeshire and Peterborough National Health Service 
Foundation Trust, Cambridge, England 
 
†† For a full list of collaborators, see Supporting Document 
 
Acknowledgements: The EU-GEI Study is funded by grant agreement HEALTH-F2-2010-241909 
(Project EU-GEI) from the European Community’s Seventh Framework Programme, and grant 
2012/0417-0 from the São Paulo Research Foundation.  
 
Abstract word count:  198 
Main body word count:  3,583  
4 
 
 
4 
 
ABSTRACT 
Purpose: The EUropean Network of National Schizophrenia Networks Studying Gene-Environment 
Interactions (EU-GEI) study contains an unparalleled wealth of comprehensive data that allows for 
testing hypotheses about i) variations in incidence within and between countries, including by 
urbanicity and minority ethnic groups; and ii) the role of multiple environmental and genetic risk 
factors, and their interactions, in the development of psychotic disorders.  
Methods: Between 2010 and 2015, we identified 2,774 with incident cases of psychotic disorders 
during 12.9 million person-years at risks, across 17 sites in six countries (UK, the Netherlands, France, 
Spain, Italy, and Brazil). Of the 2,774 incident cases, 1,130 cases were assessed in detail and form the 
case sample for case-control analyses. Across all sites, 1,497 controls were recruited and assessed. 
We collected data on an extensive range of exposures and outcomes, including demographic, clinical 
(e.g., premorbid adjustment), social (e.g., childhood and adult adversity, cannabis use, migration, 
discrimination), cognitive (e.g., IQ, facial affect processing, attributional biases), and biological (DNA 
via blood sample/cheek swab). We describe the methodology of the study and some descriptive 
results, including representativeness of the cohort. 
Conclusions: This resource constitutes the largest and most extensive incidence and case-control 
study of psychosis ever conducted.  
 
 
Keywords: case-control, environment-environment interactions, EU-GEI, first-episode psychosis, 
gene-environment interactions, incidence  
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INTRODUCTION 
The lifetime prevalence of psychotic disorders is around three per cent [1]. The associated individual, 
familial, social, and economic costs are vast. Psychotic disorders cause considerable distress to 
sufferers and their families and often lead to marked social dysfunction and exclusion. The economic 
costs are huge: in Europe, an estimated €94 billion per year [2], of which over half is due to the 
indirect costs of unemployment, lost productivity, and informal care, etc. [3]. The World Health 
Organisation estimated that in Western countries, the treatment and care of patients with a 
psychotic disorder range from 1.6% to 2.6% of total healthcare expenditures [4]. Further, individuals 
with a psychotic disorder are far more likely to have a physical health problem [5] and to die 
younger, by as much as 20 years on average, compared with the general population [6]. 
 
Our knowledge of the distribution and determinants of psychotic disorders has increased in recent 
years. The incidence varies by area (e.g., higher in some urban versus rural areas) [7,8] and social 
group (e.g., higher in some minority ethnic groups) [9,10] and, in addition to well-established genetic 
and neurodevelopmental risk factors [11,12], there is now substantial evidence implicating several 
environmental risk factors [13], such as childhood adversity [14,15] and cannabis use [16]. Pooled 
relative risks for these risk factors range between two and four, and population attributable risk 
fractions range between 20 and 35% [17,18]. Further, there is accumulating evidence that these 
myriad risk factors interact in complex ways to increase risk of psychosis via effects on the 
dopaminergic system, dysregulation of which may be the biological process that underpins the 
formation of psychotic experiences. 
 
However, there remain many gaps, inconsistencies, and unanswered questions, and recent work 
hints at different patterns of risk in different settings. For example, recent evidence has failed to 
show a universal association between city living and psychosis [19,20]. To further add to this 
conundrum, Colodro-Conde and colleagues [21] found that the high prevalence of psychosis in some 
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urban areas may be due to gene-environment selection, such that individuals with higher genetic 
loading for psychosis live in more densely populated areas. More generally, this points to a major 
limitation to our current knowledge of psychotic disorders: we know that environments affect onset 
and outcomes, but research so far has been conducted – with some important exceptions – in a 
remarkably small number of settings (i.e., select centres in the US, UK, and Australasia). Combined, 
these points emphasise the need for research in more diverse contexts to examine more nuanced 
hypotheses on the complex interplay between biology and environments in the aetiology of 
psychotic disorders. 
 
Our knowledge of psychotic disorders is limited, in part, because of heterogeneity in methods, which 
limits our ability to compare findings across populations [22]. For example, differences in study 
design (i.e. case-register, versus cohort-based designs, versus first-contact studies), the age 
structures of populations at risk, case-identification procedures, diagnostic criteria, definitions and 
measurement of environmental factors, and analytic strategies, has made cross-country comparisons 
difficult and likely obscured important clues to aetiology [23]. The only large-scale international 
comparative studies conducted to date are the World Health Organisation’s multi-country projects of 
the 1970s and 1980s, which compared the incidence and clinical and social characteristics of treated 
cases of psychoses from twelve diverse settings in ten countries using a standardised procedure for 
case identification and data collection [24]. However, since this landmark programme, there have 
been far-reaching economic and social changes (e.g. migration patterns, cannabis availability and 
use, and distribution of social risks) with conceivable impacts on the social epidemiology and 
aetiology of the psychoses. Moreover, studies of environment-gene interactions in psychotic 
disorders are rare and have typically involved small samples, with limited phenotyping and limited 
assessment of environmental factors [21,25,26].  
 
The EU-GEI programme was established to address these gaps and limitations [27]. EU-GEI is a multi-
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national research collaboration that was funded for five years (1 May 2010 – 30 April 2015). It 
consisted of 11 Work Packages [see Supplementary Table S1]. This paper profiles the incidence and 
case-control programme of work (Work Package 2), which comprises the largest multi-site study of 
psychotic disorders ever conducted. In this paper, we describe the objectives and main aspects of the 
study. 
 
Objectives 
The overall goal of the present work package was to investigate the role of multiple environmental 
and genetic risk factors, and their interactions, in the development of psychotic disorders. 
Specifically, our aims were: 1) to investigate the impact of hypothesized environmental exposures, 
measured at individual and area levels, on: a) risk of psychotic disorders; and b) high rates of disorder 
in urban areas and in migrant and minority ethnic groups; and 2) to examine hypothesized a) gene x 
environment interactions (GxE); and b) environment x environment interactions (ExE) across the life 
course.  
 
METHODS 
Study design 
The data resource comprises a multi-site population-based incidence and case-control sample of 
cases with a first episode of psychosis (International Classification of Diseases [ICD]-10 diagnoses 
F20-29 and F30-33) and controls drawn from tightly defined catchment areas in 17 sites in six 
countries (England, the Netherlands, France, Spain, Italy, and Brazil; see Figure 1). The sites were 
purposefully selected to include a mix of urban and rural areas, with varying proportions from 
minority ethnic groups (see Table 1).  
 
[Insert Fig 1 Map of EU-GEI settings for the Incidence and Case-Control Work Package] 
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Sample 
Recruitment and data collection were conducted over a five-year period between 2010 and 2015 
(Table 1). We also added data from the Veneto region, Italy, collected as part of an earlier study (the 
Psychosis Incident Cohort Outcome Study [PICOS]; 2005-2007), but with sufficiently similar methods 
to be pooled with that collected for this study. The incidence sample comprised 2,774 individuals 
with a first episode of psychosis. Of these, 1,519 were approached, and 1,130 were consented and 
assessed (41% of the total incidence sample). Reasons for non-participation among cases who were 
approached were: refusal to participate, language barriers, and exclusion after consenting as they did 
not meet the age inclusion criteria. In addition, 1,497 controls were recruited and assessed.  
 
[Insert Table 1] 
 
Statistical power 
Our sample of 1,130 cases and 1,497 controls has high statistical power to test our primary study 
hypotheses, even after accounting for missing data and for the current necessity of restricting 
genetic analyses to individuals of non-African ancestry. For example, in a restricted sample of cases 
1,031 and 1,438 controls, we have greater than 80% power to detect an interaction odds ratio of 1.2 
at p <= 0.05, assuming an odds ratio of 2.0 for an environmental exposure and of 1.2 for each unit 
increase in polygenic score (assuming N (0,1) distribution).  
 
Case ascertainment and recruitment 
All cases presenting to one of the 17 participating centres in 6 countries with a suspected first 
episode of psychosis were potentially eligible for inclusion in the study. The inclusion criteria for 
cases were: a) presence of at least one positive psychotic symptom for at least one day duration or 
two negative psychotic symptoms (for at least six months duration) within the time-frame of the 
study; b) aged between 18 and 64 years (inclusive); and c) resident within a clearly defined 
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catchment area at the time of their first presentation. Residence was defined as a minimum of a one 
night stay at a residential address within the catchment areas. Exclusion criteria were: a) previous 
contact with specialist mental health services for psychotic symptoms outside of the study period at 
each site; b) evidence of psychotic symptoms precipitated by an organic cause (ICD-10: F09); c) 
transient psychotic symptoms resulting from acute intoxication (F1X.5); d) severe learning 
disabilities, defined by an IQ less than 50 or diagnosis of intellectual disability (F70 to F79); and, for 
the case-control part only, e) insufficient fluency of the primary language at each site to complete 
assessments. 
 
Case identification procedures involved teams of researchers regularly screening both general adult 
and specialist mental health services (both in- and out-patient). The screening process involved 
researchers regularly liaising with clinical staff and checking clinical records to identity potential 
cases. The researchers only included those individuals who they could be sure met the criteria based 
on the symptoms reported in the clinical notes. Potential cases were then approached when 
considered appropriate by clinical staff and informed consent sought.  
 
Control recruitment 
Inclusion criteria for controls were: a) aged between 18 and 64 years; b) resident within a clearly 
defined catchment area at thetime of consent into the study; c) sufficient command of the primary 
language at each site to complete assessments; and d) no current or past psychotic disorder. To 
select a population-based sample of controls broadly representative of local populations in relation 
to age, gender, and ethnicity, a mixture of random and quota sampling was used. Quotas for control 
recruitment were based on the most accurate local demographic data available. Quotas were then 
filled using a variety of recruitment methods, including through: 1) random sampling from lists of all 
postal addresses (e.g., in London); 2) stratified random sampling via GP lists (e.g., in London and 
Cambridge) from randomly selected surgeries; and 3) ad hoc approaches (e.g., internet and 
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newspaper adverts, leaflets at local stations, shops, and job centers). In some sites (e.g., London), 
some groups (e.g., black African and black Caribbean) were oversampled to enable subsequent sub-
group analyses. To deal with this in subsequent analyses, weights were generated, based on the 
most accurate local demographic data available, to minimize any resulting bias in estimating the 
prevalence of exposures among controls.  
 
Individuals who agreed to take part were screened for a history of psychosis. Those who reported 
previous or current treatment for psychosis were excluded. Those who responded positively to any 
question in the screening instrument, indicating a possible psychotic experience, were interviewed 
further with standardised interviews to assess symptoms and to establish presence or otherwise of a 
psychotic disorder. On this basis, no potential controls were found to have a past or current 
psychotic disorder.  
 
Data contents 
We collected data on an extensive range of exposures and outcomes across multiple domains using 
previously validated questionnaires, tasks, and procedures: demographic, clinical, social, 
psychological, cognitive, and biological (Table 2). All environmental exposures and cognitive and 
psychological tests were measured using previously validated questionnaires and tasks.  
 
Genetic risk was assessed both indirectly, using a familial liability score for psychosis [28], and 
directly, using DNA extracted from two 9ml non-fasting venous blood samples and/or via saliva 
samples (Oragene). Samples were genotyped using custom Illumina HumanCoreExome-24 BeadChip 
genotyping arrays containing probes for 570,038 genetic variants (Illumina Inc., San Diego, CA). 
Genotype data were called using the GenomeStudio package, transferred into PLINK format for 
further analysis, and underwent quality control based on genotype variants and samples.  
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[Insert Table 2] 
 
Quality assurance and control 
Prior to and during data collection, annual multi-site meetings were arranged to bring together 
principal investigators and core researchers to ensure that standardised procedures were being 
implemented, to provide training, to discuss issues with data collection, and to conduct inter-rater 
reliability exercises. The study was designed to ensure comparable procedures and methods across 
settings, with some local adaptation to allow for variations in healthcare provision and health service 
contact points. The primary deviation from protocol was in the Veneto region, Italy, where data were 
derived from a previous study which used comparable methods [29], but had a lower upper-age limit 
of 54.   
 
Training of researchers who were responsible for administrating the assessments was performed at 
the outset and throughout the study. This was organised by a technical working committee of the 
overall EU-GEI study (Work Package 11). An online resource was made available with taped 
interviews, samples of recordings, and written summaries for staff training purposes. Inter-rater 
reliability was assessed annually. Researchers were required to attain and maintain a minimum 
threshold of correct ratings before being allowed to administer the core assessments. Sufficient 
levels of inter-rater reliability for the core measurements, ranging from 0.70-0.91, were achieved, 
and are shown in Table 3. 
 
[Insert Table 3] 
 
Data management 
Data was collected on paper and, for some cognitive tasks (e.g., the White Noise task), on laptops 
and securely stored at each of the participating centres, and was entered locally using an encrypted 
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web-based system, using commercial software (4D) that was adapted specifically for EU-GEI 
purposes. Data was entered once with field codes restricted to logical values where possible, to 
minimise data entry errors. Blood or saliva samples were taken at approved clinical research facilities 
by an experienced researcher, were fully anonymized and identified by bar code, and sent to the 
Institute of Psychological Medicine and Clinical Neurology at Cardiff University for genotyping. The 
data resource has undergone a rigorous period of validation checks and cleaning by a small number 
of experienced researchers. This has involved checks of missing data and corroboration of these 
against the paper files at each of the 17 sites.  
 
Ethical approval 
All participants who agreed to take part in the study provided informed, written consent following 
full explanation of the study. Ethical approval for the study was provided by relevant research ethics 
committees in each of the study sites [30].  
 
RESULTS 
Sample representativeness and characteristics 
There were similar proportions from minority ethnic groups among consented and non-consented 
cases (43% vs. 40%). However, the proportion of men and the proportions in younger age groups 
were higher among consented, compared with non-consented, cases (men: 62% vs. 57%; aged 18 to 
34 years: 69% vs. 60%) (Table 4a). Compared with the general population, controls were more likely 
to belong to a minority ethnic group (controls: 28%, population at-risk: 23%) and were younger (aged 
between 18 to 34 years, controls: 56%, population at-risk: 38%) (Table 4b). The greater proportion of 
controls who were from ethnic minority reflects oversampling in some sites (e.g., London) to enable 
subsequent sub-group analyses. 
 
Cases were younger than controls (median age of cases was 29 years (interquartile range [IQR] 22-
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37), and controls 33 years old (IQR 26-47)). Compared with controls, a greater proportion of the 
cases were men (62% vs. 49%), migrants (28% vs. 22%), and left school without any qualifications 
(16% versus 6%); a smaller proportion was of white ethnicity (63% versus 73%) (see Supplementary 
Table S2). 
 
[Insert Table 4] 
 
DISCUSSION 
This study was conducted in a diverse range of settings across Europe and one setting in Brazil, 
selected to ensure a mix of urban and rural areas with large migrant and ethnic minority populations. 
This maximises its applicability to and importance for public health initiatives, with potential 
implications for both prevention and intervention, particularly among minority ethnic groups, and in 
urban areas, and in relation to cannabis and other substance use and developmental adversity. Our 
primary hypotheses centre on examining variations in incidence and symptoms, environmental risk 
factors, and the interplay between environment and genetic factors in the development of psychotic 
disorders.  
 
Incidence and symptoms 
We have already published findings of the overall variations in incidence of psychoses by site [30]. 
Our findings suggest marked geographical differences in the incidence of psychotic disorders, with 
around an 8-fold variation among study sites after accounting for age, sex, and minority ethnic 
status. At an area level, initial analyses suggest that some of this variation may be related to the 
proportion of owner-occupied homes in an area (a tentative proxy for social cohesion or 
socioeconomic deprivation), i.e., areas with more owner-occupied homes had, on average, lower 
rates of psychotic disorder. Analyses of variations in incidence by ethnic group are ongoing. Analyses 
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of symptom data on incident cases, collated using the OPCRIT, have examined the validity of a 
transdiagnostic dimensional structure of psychopathology and, in doing so, have challenged the 
common binary categorisation of psychoses into non-affective and affective disorders [31]. Our 
findings suggest that a bifactor model of psychopathology, comprising one general factor and five 
dimensions (positive, negative, manic, disorganised, and depressive symptoms), best represents the 
structure of symptoms among those with a psychotic disorder. We further found: compared with 
majority populations, cases in minority ethnic groups scored higher on the positive psychotic 
symptom dimension; and, compared with rural areas, cases in urban areas scored higher on the 
general symptom dimension.  
 
Environmental risk 
The initial focus of analyses of our case-control data resource are the associations and population 
impact of putative environmental risk factors, including childhood adversity and abuse, adult 
adversity, discrimination, and cannabis use. In analyses of cannabis use data, for example, we found 
that, compared with those who did not use cannabis, the odds of psychosis were: (1) around 3 times 
higher among those who used cannabis daily; (2) around 2 times higher among those who spent 
more than 20 Euros a week on cannabis; and (3) around 50% higher among those who used cannabis 
high in THC [32]. In addition, we found variations in population attributable fractions for daily 
cannabis use on psychosis [32], with population attributable fractions (i.e., the proportion of 
psychosis, assuming causality, attributable to daily use) ranging from 1% (in Puy-de-Dôme, France) to 
44% (in Amsterdam). Similar analyses examining childhood and adult adversity are ongoing, focusing 
on type, severity, and age of exposure (Morgan et al., in preparation).  
 
These analyses will be further extended to examine environment-environment and gene-
environment interactions and to more clearly elucidate the pathogenic processes underpinning 
observed variations in incidence across study sites [30] and high rates of psychotic disorders in urban 
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areas [7,8], and in migrant and ethnic minority groups [9,10].  
 
Strengths and weaknesses 
To our knowledge, this is the most extensive multi-site incidence and case-control study of first-
episode psychosis ever conducted, with comprehensive data on a variety of environmental, 
psychological, and genetic risk factors. The primary strength of the EU-GEI study is its potential to 
provide ground-breaking and important information about the development of psychoses, by 
investigating the complex interrelationships between candidate environmental, psychological, and 
biological (genetic) factors and psychotic disorders, including the mechanisms through which they 
increase risk. In addition, given that our study was carried out in major urban and rural sites with 
heterogeneous populations suggests that our external validity may extend to other centres with 
similar population profiles. The combined incidence and case-control methodology allows for precise 
identification of, and ability to account for, any potential selection biases amongst the recruited and 
assessed cases. The richness of the exposure information available will allow for more nuanced 
analyses and a more fine-grained understanding of their impact on psychotic disorder than has been 
possible to date. Importantly, the inclusion of only cases with a first episode of psychosis (rather than 
individuals with long-standing disorder) allows inferences to be made about causal connections and 
processes. 
 
The primary limitation of this data resource relates to case identification. As in all previous studies, 
we relied on first contact with mental health services as a proxy for first onset. While it is likely most 
individuals who develop a psychotic disorder do present to services, at least in sites with well-
developed public health systems, some who do not present will be missed and this may introduce 
selection biases.  Any rate estimates should therefore be considered as treated incidence. Further, 
variations in referral procedures of patients with psychosis from primary to secondary mental health 
care settings and in the organization of secondary mental health care services across catchment 
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areas may have influenced the identification of cases, and may explain some of the variation in 
estimates of incidence across study sites and countries. For example, unlike in other settings, 
patients in Madrid are not constrained to using mental health services in their residential catchment 
areas [33]. However, as highlighted by Jongsma et al. (2018) [30], the divergences in service provision 
and cultural context are unlikely to fully explain the 8-fold variation in incidence across sites. 
 
There are also several limitations that are inherent to case-control designs. First, while substantial 
efforts were made at the outset to reduce the potential biases in the identification of cases (e.g., 
recruitment of participants from a number of sources using a variety of methods, including inpatient 
wards and community teams) and controls (e.g., use of mixture of random and quota sampling), we 
were not entirely successful; our cases are not fully representative of the sample identified in the 
incidence study, and our controls not of the population-at-risk. For example, reliance in some sites 
on recruitment of controls through ad hoc methods, such as newspaper advertisements, may have 
biased samples. Interpretations of estimated effects (odds ratios) should be considered with this in 
mind. 
 
Second, there is the potential for both recall and observer bias. In order to minimise these, and 
validate environmental exposures, several steps were taken. For core environmental exposures (e.g. 
childhood adversity and cannabis use), we used extensive, well-validated measures, that drew on life 
course methods to anchor memories and improve recall. All researchers administering these 
assessments went through intensive training, with regular top-ups. Further, where possible, we drew 
on corroborative sources of information in the assessment of exposure to childhood and adulthood 
adversity (e.g. clinical records, interviews with siblings of a subsample of cases (n = 272)).  
 
Third, measurement of exposure occurred after onset of disorder, making causal inferences 
problematic. To establish the temporal ordering of exposure and outcome, we carefully established 
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the date of onset of disorder and, for measures of exposures in childhood and adulthood, ensured 
that all assessments related to the period pre-onset.  
 
Finally, given the large battery of tests and interviews conducted with our participants, data were 
missing for some assessments, particularly towards the end of the study battery. Where appropriate, 
a standardised procedure for multiple imputation will be used to minimise the loss of precision or 
selection biases which may otherwise be introduced in complete case analyses. 
 
Data resource access 
The EU-GEI WP2 principal investigators [contact: craig.morgan@kcl.ac.uk] welcome formal requests 
for access to the data, biological samples, and/or collaborative projects. Researchers will be required 
to complete an EU-GEI WP2 data interest form to state their intended hypotheses and analysis plan, 
which will be reviewed by the PIs to determine whether the proposal can be addressed by this data 
resource, does not duplicate on-going or completed analyses with this dataset, and lies within the 
scope of current ethical approvals. More information about the study can be found on the study 
website (http://www.eu-gei.eu/). 
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